Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
- Status
- ENROLLING_BY_INVITATION
- Phase
- NA
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
- Status
- COMPLETED
- Phase
- N/A
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
IMM60 and Pembrolizumab in Melanoma and NSCLC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of EBC-129 in Advanced Solid Tumours
- Status
- RECRUITING
- Phase
- PHASE1
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC
- Status
- TERMINATED
- Phase
- PHASE2